There is limited research comparing HHUS and ABUS in second-look settings despite the fact that these exams are routinely utilized as supplemental imaging tools. 

Not all fat is created equal, and some specific types carry more neurological consequences than others, according to new research. 

Researchers see potential for this technology to make cardiac screening much easier for physicians who are not trained cardiologists.

More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.

Chris Waddell, a medtech executive focused on various structural heart technologies, is leaving Abbott after several years to "recharge" and pursue a new opportunity.

The elective exams have previously been delivered under the SimonONE brand and will be folded into the rest of the radiology practice for greater service integration.

Tim Szczykutowicz, PhD, associate professor radiology, University of Wisconsin Madison, explains the new technology developments in GE HealthCare's  FDA 510(k)-pending photon-counting CT scanner. 

New York-based PE firm Towerbrook Capital has bought a controlling stake in the imaging group, with Madison Dearborn Capital the seller.